SLC2A3 and lung adenocarcinoma: However, SLC2A3 expression levels were significantly lower in nine types of cancer, including bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical and endocervical cancer (CESC), glioblastoma multiforme (GBM), kidney chromophobe (KICH), kidney renal papillary carcinoma (KIRP), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and uterine corpus endometrial carcinoma (UCEC).